1 free read left. Create a free account for unlimited reading + AI research.
Create free accountFinancial report
Turtle Beach
Turtle Beach Corporation’s financial performance for the first quarter of 2016 reflects a period of revenue growth tempered by persistent net losses and significant structural challenges. The company reported a net loss of $12.0 million on $24.0 million in revenue, an increase in loss compared to the $10.6 million deficit recorded during the same period in 2015. Despite these losses, the company achieved an improved Adjusted EBITDA of $(6.3) million, supported by strong headset sales and internal cost-reduction initiatives. To bolster liquidity, the firm utilized $6.0 million from a February 2016 equity offering to pay down revolving credit balances, and management maintains that current capital resources are sufficient to meet operational needs for the upcoming year.
The company’s financial stability remains heavily contingent upon its ability to navigate complex debt obligations and stringent covenant requirements. Turtle Beach has secured amendments to its credit facilities, including the suspension of consolidated leverage ratio testing through April 2017, to avoid potential defaults. However, the firm faces substantial operational risks, including a high concentration of sales among three primary clients and a heavy reliance on third-party gaming platforms like Microsoft and Sony. Furthermore, the company is managing a voluntary product recall for its XO FOUR Stealth headsets and continues to address a material weakness in internal controls regarding goodwill impairment assessments.
Strategic focus is currently split between the transition to new-generation gaming consoles and the expansion of HyperSound technology into the hearing healthcare market. This diversification effort carries inherent risks, as the market performance of the HyperSound Clear 500P remains a critical factor in potential future goodwill impairment. With 68% of its stock held by a single group, the company operates as a controlled entity, concentrating strategic decision-making power while facing ongoing pressures from stockholder litigation, supply chain volatility, and the regulatory demands of the medical device sector.
Turtle Beach · 2026
Jason Schreier · 2026